(Q28137879)

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Genetics of hyperactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

The Dopamine D2 Receptor Locus as a Modifying Gene in Neuropsychiatric Disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Male testosterone linked to high social dominance but low physical aggression in early adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

An indication for use of imipramine in attention deficit disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Is attention deficit hyperactivity disorder familial?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Neurobiology of attention-deficit hyperactivity disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Imipramine in the Treatment of Minimal Brain Dysfunction in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Motor performance in hyperactive children treated with imipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Guanfacine, but not clonidine, improves planning and working memory performance in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Psychoactive drugs in the immature organism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

The role of frontal lobe dysfunction in childhood hyperkinesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

The Psychiatric Status of the Legal Families of Adopted Hyperactive Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Catecholamines in attention-deficit hyperactivity disorder: current perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

One-year follow-up of hyperactive boys treated with imipramine or methylphenidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Electrodermal correlates of hyperactivity in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Bupropion treatment of attention-deficit hyperactivity disorder in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Imipramine and methylphenidate in hyperactive children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

A naturalistic assessment of protriptyline for attention-deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Nortriptyline in the treatment of ADHD: a chart review of 58 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Combining methylphenidate and clonidine: a clinically sound medication option

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Effects of Imipramine and Dextroamphetamine on Behavior of Neuropsychiatrically Impaired Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Amitriptyline and methylphenidate treatment of behaviorally disordered children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4

Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900192-4